Does kynurenic acid act on nicotinic receptors? An assessment of the evidence
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
As a major metabolite of kynurenine in the oxidative metabolism of tryptophan, kynurenic acid is of considerable biological and clinical importance as an endogenous antagonist of glutamate in the central nervous system. It is most active as an antagonist at receptors sensitive to N‐methyl‐D‐aspartate (NMDA) which regulate neuronal excitability and plasticity, brain development and behaviour. It is also thought to play a causative role in hypo‐glutamatergic conditions such as schizophrenia, and a protective role in several neurodegenerative disorders, notably Huntington’s disease. An additional hypothesis, that kynurenic acid could block nicotinic receptors for acetylcholine in the central nervous system has been proposed as an alternative mechanism of action of kynurenate. However, the evidence for this alternative mechanism is highly controversial, partly because at least eight earlier studies concluded that kynurenic acid blocked NMDA receptors but not nicotinic receptors and five subsequent, independent studies designed to repeat the results have failed to do so. Many studies considered to support the alternative ‘nicotinic’ hypothesis have been based on the use of analogs of kynurenate such as 7‐chloro‐kynurenic acid, or putatively nicotinic modulators such as galantamine, but a detailed analysis of the pharmacology of these compounds suggests that the results have often been misinterpreted, especially since the pharmacology of galantamine itself has been disputed. This review examines the evidence in detail, with the conclusion that there is no confirmed, reliable evidence for an antagonist activity of kynurenic acid at nicotinic receptors. Therefore, since there is overwhelming evidence for kynurenate acting at ionotropic glutamate receptors, especially NMDAR glutamate and glycine sites, with some activity at GPR35 sites and Aryl Hydrocarbon Receptors, results with kynurenic acid should be interpreted only in terms of these confirmed sites of action. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523 · cited 2×
“…for a major role of NMDA receptors in synaptic transmission and plasticity including learning and memory and other aspects of cognition (Tsien et al. 1996; Cammarota et al. 2000; Bartlett et al. 2007; Berberich et al. 2007; Zorumski and Izumi 2012; Paoletti et al. 2013; Mukherjee et al. 2014).”
BackgroundAn endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory.
Tsien, J. Z., Huerta, P. T., & Tonegawa, S. (1996) · Cell · doi:10.1016/s0092-8674(00)81827-9 · Cited by 1,782
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530 · cited 2×
“…in countless reports since 1982 as detailed below, with kynurenate rapidly becoming a routine tool for the exploration of glutamate’s physiological activity and pathological relevance (see Stone and Burton 1988; Stone 1993; Stone and Darlington, 2002; Moroni et al. 2012; Schwarcz et al. 2012).”
BackgroundPresynaptic nicotinic ACh receptors
Wonnacott, S. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10073-4 · Cited by 1,308 · cited 2×
“This would also be consistent with indications that most central nicotinic receptors are functionally expressed mainly on presynaptic terminals with their main function to modulate the release of neurotransmitters (Wonnacott, 1997) (see below).”
BackgroundNicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070 · cited 2×
“Nicotinic receptors can regulate the release of, at least, glutamate (McGehee et al., 1995; Gray et al., 1996; Albuquerque et al. 2009; Gu et al., 2012; Puddifoot et al. 2015; Pistillo et al. 2015, 2016; Howe et al. 2016; Ryu et al. 2017) and can modulate the release of GABA (Gray et al., 1996; Le…”
BackgroundNicotinic Receptors in the Development and Modulation of CNS Synapses
Role, L. W., & Berg, D. K. (1996) · Neuron · doi:10.1016/s0896-6273(00)80134-8 · Cited by 762
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751
Self-citationInflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
Long-term potentiation of excitatory inputs to brain reward areas by nicotine
Mansvelder, H. D., & McGehee, D. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00042-8 · Cited by 720
Quinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303 · cited 1×
“Subsequent reports have claimed that the drug was also an Allosteric Potentiating Ligand at nicotinic receptors with several subunit compositions (Maelicke et al. 2001; Samochocki et al. 2003; Albuquerque et al. 2009; Liu et al 2010).”
BackgroundKynurenine pathway in depression: a systematic review and meta-analysis
Ogyu, K., Kubo, K., Noda, Y., Iwata, Y., Tsugawa, S., Omura, Y., Wada, M., Tarumi, R., Plitman, E., Moriguchi, S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.023 · Cited by 301 · cited 1×
“Schizophrenia, for example, has been linked closely with kynurenic acid concentrations in the CNS (Stone and Darlington 2013; Cho et al. 2017; Plitman et al. 2017; Erhardt et al. 2017; Ogyu et al. 2018; Laumet et al. 2017; Dantzer et al. 2011; Kindler et al. 2019).”
BackgroundNicotinic Receptor Activation Excites Distinct Subtypes of Interneurons in the Rat Hippocampus
McQuiston, A. R., & Madison, D. V. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-02887.1999 · Cited by 239
Schilström, B., Svensson, H. M., Svensson, T. H., & Nomikos, G. G. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00114-6 · Cited by 207
Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex
Yang, Y., Paspalas, C. D., Jin, L. E., Picciotto, M. R., Arnsten, A. F. T., & Wang, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307849110 · Cited by 188 · cited 2×
“…such as the ability of nicotinic receptor to up- or down-regulate the expression of glutamate receptors (Pistillo 2015, 2016) and may account for the report that activation of a7nicotinic receptors is required for the activation of NMDA receptors in the prefrontal cortex (Yang et al. 2013).”
BackgroundParikh, V., Ji, J., Decker, M. W., & Sarter, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5712-09.2010 · Cited by 133
Livingstone, P. D., Srinivasan, J., Kew, J. N. C., Dawson, L. A., Gotti, C., Moretti, M., Shoaib, M., & Wonnacott, S. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06613.x · Cited by 133 · cited 1×
“…release of GABA (Gray et al., 1996; Le Magueresse et al., 2006), dopamine (Schilstrom et al., 1998a,b; Kaiser and Wonnacott 2000; Livingstone and Wonnacott, 2009; Livingstone et al. 2009) and norepinephrine (Pittaluga and Raiteri 1992; Pittaluga et al. 1992; Raiteri et al. 1992; Li et al., 1998).”
BackgroundParikh, V., Man, K., Decker, M. W., & Sarter, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5251-07.2008 · Cited by 127 · cited 1×
“The two major subtypes of CNS nicotinic receptors, a7 and a4b2 are expressed on cell bodies and synaptic terminals (Wonnacot, 1997; Parikh et al. 2008, 2010; Puddifoot et al. 2015; Howe et al. 2016) where they promote the influx of extracellular calcium leading to the release of neurotransmitters…”
BackgroundAlkondon, M., Pereira, E. F. R., Barbosa, C. T. F., & Albuquerque, E. X. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37139-3 · Cited by 127
Kynurenic acid antagonists and kynurenine pathway inhibitors
Stone, T. W. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.4.633 · Cited by 79
Self-citationGrilli, M., Patti, L., Robino, F., Zappettini, S., Raiteri, M., & Marchi, M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05307.x · Cited by 40
Cited by
Tryptophan Metabolism as a Pharmacological Target
Modoux, M., Rolhion, N., Mani, S., & Sokol, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.006 · Cited by 284
Mithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Self-citationKynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · doi:10.20944/preprints202503.2399.v1 · Cited by 30
Metadata
- Authors
- Stone, T. W.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2019-11-24
- Volume
- 152
- Issue
- 6
- Pages
- 627-649
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2988690127
- Cited by
- 117
- References
- 27
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.